一款COVID-19的潜在疗法:糖核苷类似物EIDD-2801,已启动II期临床试验

2020-06-21 Allan MedSci原创

EIDD-2801是一种新型核糖核苷类似物,可抑制多种RNA病毒的复制,包括SARS-CoV-2。

截至北京时间6月21日8时,全球COVID-19累计确诊病例突破890万例,达到8,906,137例,累计死亡病例超过46.6万例。

Ridgeback Biotherapeutics宣布启动两项II期临床试验,以测试EIDD-2801作为抗COVID-19的抗病毒药物的功效。最近的I期临床试验已确定EIDD-2801是安全的,且能有效抵抗SARS-CoV-2。EIDD-2801将在两项II期研究中用于治疗18岁及以上的患者。

EIDD-2801是一种新型核糖核苷类似物,可抑制多种RNA病毒的复制,包括SARS-CoV-2。在对两种不同冠状病毒(SARS-CoV-1和MERS)的动物研究中,EIDD-2801能够改善肺功能,减少体重减轻并减少肺中的病毒载量。

为了确保EIDD-2801在被证明可以有效治疗COVID-19的情况下迅速被患者使用,Ridgeback一直在自行承担风险和费用生产了数十万剂EIDD-2801。Ridgeback Biopharmaceuticals的首席执行官Wendy Holman表示:“如果临床试验获得成功,则必须立即向全世界提供充足的药品”。

 

原始出处:

https://www.firstwordpharma.com/node/1734111?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2088811, encodeId=eeac2088811ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Apr 30 01:09:55 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049615, encodeId=e372204961510, content=<a href='/topic/show?id=5bf5621463a' target=_blank style='color:#2F92EE;'>#核苷类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62146, encryptionId=5bf5621463a, topicName=核苷类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Jan 18 14:09:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653044, encodeId=9b77165304419, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Aug 07 08:09:55 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931516, encodeId=92f71931516c6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Apr 04 06:09:55 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524827, encodeId=c04d152482eb6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Jun 23 01:09:55 CST 2020, time=2020-06-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2088811, encodeId=eeac2088811ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Apr 30 01:09:55 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049615, encodeId=e372204961510, content=<a href='/topic/show?id=5bf5621463a' target=_blank style='color:#2F92EE;'>#核苷类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62146, encryptionId=5bf5621463a, topicName=核苷类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Jan 18 14:09:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653044, encodeId=9b77165304419, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Aug 07 08:09:55 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931516, encodeId=92f71931516c6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Apr 04 06:09:55 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524827, encodeId=c04d152482eb6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Jun 23 01:09:55 CST 2020, time=2020-06-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2088811, encodeId=eeac2088811ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Apr 30 01:09:55 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049615, encodeId=e372204961510, content=<a href='/topic/show?id=5bf5621463a' target=_blank style='color:#2F92EE;'>#核苷类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62146, encryptionId=5bf5621463a, topicName=核苷类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Jan 18 14:09:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653044, encodeId=9b77165304419, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Aug 07 08:09:55 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931516, encodeId=92f71931516c6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Apr 04 06:09:55 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524827, encodeId=c04d152482eb6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Jun 23 01:09:55 CST 2020, time=2020-06-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2088811, encodeId=eeac2088811ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Apr 30 01:09:55 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049615, encodeId=e372204961510, content=<a href='/topic/show?id=5bf5621463a' target=_blank style='color:#2F92EE;'>#核苷类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62146, encryptionId=5bf5621463a, topicName=核苷类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Jan 18 14:09:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653044, encodeId=9b77165304419, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Aug 07 08:09:55 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931516, encodeId=92f71931516c6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Apr 04 06:09:55 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524827, encodeId=c04d152482eb6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Jun 23 01:09:55 CST 2020, time=2020-06-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2088811, encodeId=eeac2088811ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Apr 30 01:09:55 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049615, encodeId=e372204961510, content=<a href='/topic/show?id=5bf5621463a' target=_blank style='color:#2F92EE;'>#核苷类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62146, encryptionId=5bf5621463a, topicName=核苷类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Mon Jan 18 14:09:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653044, encodeId=9b77165304419, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Aug 07 08:09:55 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931516, encodeId=92f71931516c6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Apr 04 06:09:55 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524827, encodeId=c04d152482eb6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue Jun 23 01:09:55 CST 2020, time=2020-06-23, status=1, ipAttribution=)]

相关资讯

NEJM:肾素-血管紧张素系统阻滞剂与Covid-19风险

在这项基于人群的大型研究中,由于Covid-19患者的心血管疾病患病率较高,因此在Covid-19患者中使用ACE抑制剂和ARB的比例高于对照者。没有证据表明ACE抑制剂或ARB会影响COVID风险。

Nature:冠状病毒大突破:地塞米松,可以挽救重症新冠患者生命的药物

导言:在COVID-19席卷全球后,其治疗药物就一直层出不穷,先是瑞德西韦,到后面的氯喹、羟氯喹,再到后面的康复患者的血浆中的抗体等等,都没有显示出明显的疗效,关于COVID-19,最近英国有了一项大

Lancet Rheumato:Mavrilimumab可改善重症COVID-19肺炎临床结果

对于非机械通气的重症COVID-19肺炎和全身过度炎症患者,在标准护理基础上添加Mavrilimumab可显著改善临床结果

截至6月19日24时国内新型冠状病毒肺炎(COVID-19)疫情全新情况

6月19日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例27例,其中境外输入病例4例(广东3例,上海1例),本土病例23例(北京22例,河北1例);无新增死亡病例

Neurology:COVID-19感染者新发神经系统事件

近日,神经病学领域权威杂志Neurology上发表了一篇研究文章,该研究旨在调查与冠状病毒病2019(COVID-19)相关的新发神经系统损害。

NEJM:肾素-血管紧张素-醛固酮系统抑制剂与Covid-19风险

该研究发现服用五种常见降压药物的检测阳性患者中,Covid-19阳性的可能性或发生严重Covid-19的风险没有实质性增加。

拓展阅读

Critical Care Medicine:气道压力释放通气模式在COVID-19导致急性呼吸 衰竭的患者中的应用:一项单中心随机对照试验

与小潮气量机械通气相比,APRV通气模式并未缩短重症新冠肺炎机械通气患者的机械通气时间,也未改善患者的其他临床结局。

Radiology:超极化氙气MRI显示长期COVID患者的肺部异常

胸部X线片(CXR)是诊断急性COVID-19肺炎最常用的成像方式,对于需要入院治疗的患者,通常会在急性感染三个月后重复检查。

Radiology:基于胸部CT的COVID-19肺炎后1年的预后评估

胸部CT对疾病监测至关重要,时间是充分评估肺部恢复能力的关键因素。

Am J Resp Crit Care:半乳糖凝集素-3抑制剂治疗COVID-19肺炎

在COVID-19肺炎中,吸入GB013治疗的耐受性良好,达到了临床相关的血浆浓度。该研究的数据支持更大规模的临床试验来明确GB013的临床疗效。

European Radiology:如何实现影像学的标准COVID-19全自动预测?

放射组学是一种利用数学算法量化医学成像中病变的表型特征的方法,可用于预测疾病的严重程度和进展。

Lenzilumab 治疗 COVID-19 住院患者,未达到主要终点

FDA 已经拒绝了该公司寻求紧急使用该疗法治疗新住院 COVID-19 患者的请求。美国监管机构确定,它无法得出 lenzilumab 的潜在益处超过潜在风险的结论。